In Copan Italia S.p.A. et al. v. Puritan Medical Products Company LLC et al., the Federal Circuit addressed the issue of whether the Federal ...
Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments 2-5 Novartis continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback